Trending...
- Janie's Art Journals Selected to Showcase at Inaugural Fiber+Fabric Craft Festival, May 1-3, 2026
- Documented Pattern of Racial Bias Linked to Former Newspaper Editor Spans Two Major U.S. Newsrooms
- Chicago: CTA Celebrates Start of The Historic Red Line Extension Project by Breaking Ground at The Future Michigan Avenue Station
CHICAGO, June 22, 2025 ~ A recent study has revealed that oral semaglutide, a medication used to treat type 2 diabetes, can significantly reduce the risk of cardiovascular events by 14%. The results were presented at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago as a late-breaking symposium.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
- Chicago: Mayor Brandon Johnson Announces the Full Restoration of the Department of Environment
- Nayarit's Jungle Coast Redefines Luxury Travel on Mexico's Pacific Now More Accessible Than Ever
- Indies United is pleased to present our May 2026 book releases
- Naperville: Structure Fire in the 500 Block of South Route 59
- Naperville: Structure Fire in the 3000 Block of Tussell Street
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
- $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
- Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
- RAS AP Consulting Launches Vendor Master File & Payment Controls Assessment for NACHA Phase 2 Compliance
- New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
- Chicago: Mayor Brandon Johnson, Mayor's Office of Reentry Host Reentry Convening Honoring Second Chance Month
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
Filed Under: Business
0 Comments
Latest on illi News
- Food Journal Magazine Unveils Its Latest 'Best of Los Angeles' Culinary Discoveries
- Boston Industrial Solutions Launches Natron® 717S Series: A New Flexible UV LED Ink for Ricoh GH2220 Printheads
- 5 Things NYC Courier Services Won't Tell You About How Same-Day Delivery Actually Works
- Tropidelic Links Up With International Reggae Star Collie Buddz and Eli Mac for Feel-Good Breakthrough Single "Follow Your Nature"
- Save 15 Percent on Florida Keys Accommodations with KeysCaribbean's 'Advance Purchase Rate Discount'
- STLE Hosts Virtual Symposium on Additives, July 21-22, 2026
- Atelier 411 Studios and Columbus Fashion Council Present Red Carpet Experience at Gateway Film Center for The Devil Wears Prada 2
- Hazel E Celebrates Birthday with Luxury "Goddess" Yacht Experience in Marina del Rey
- Joseph Neibich sits down with Bold Jounrey (aka Joseph Nybyk)
- AI Suite 360 Launches Done-For-You AI Implementation to Rescue SMBs from the "Frankenstein Tax"
- CX Network Releases Report on the Best AI Support Tools for SaaS Companies 2026
- Outlier Pest Season Hits Willamette Valley as Mild Winter Drives Early Surge in Ant and Rodent Activity
- Chicago: Mayor Brandon Johnson Announces Appointment of David Glockner as Inspector General
- From Potential to Proficiency: Celebrating Growth and Creative Problem Solving at VGA
- Chicago: Mayor Brandon Johnson Breaks Ground on Southbridge Phase 1C, Advancing 80 New Affordable Homes in the South Loop
- Lokal Media House Wins Web Excellence Award for Black Plumbing Redesign
- Chicago: Mayor Brandon Johnson Signs Peacebook Executive Order, Establishing Year-Round Youth Peacekeeping Program
- Lick Expands Flavored Massage Oil Collection with 10 New Indulgent Cream-Inspired Scents
- New Research Identifies "Vacation Compatibility Gap" as the Hidden Force Shrinking How Long and With Whom Americans Travel
- Melospeech Inc. Awarded New NYSDOH BEI Contract in New York